Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breast
Breast Cancer · 2025
DOI: 10.1007/s12282-025-01706-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer, 2025. Verfasst von Yuko Takano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, 65 Tsurumai-Cho, Showa-Ku, Nagoya, Aichi, 466-8550, Japan. takano.yuko.…. Hauptthemen laut MEDLINE: Breast Neoplasms, Carcinoma, Lobular, Biomarkers, Tumor, Carcinoma, Ductal, Breast. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nagoya University.
Abstract (Originalsprache)
Background
High tumor mutational burden (TMB-H) is an established biomarker for a favorable response to immune checkpoint inhibitors. However, tumor mutational burden (TMB) in invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) has not been sufficiently investigated.
Methods
We collected data of patients with ILC or IDC from the Center for Cancer Genomics and Advanced Therapeutics database between June 2019 and August 2023. Furthermore, we examined the clinicopathological factors and TMB status.
Results
Patients with ILC (n = 170) had a median TMB score of 4.00 mut/Mb (interquartile range, 2.00–7.14 mut/Mb), whereas those with IDC (n = 2598) had a score of 3.90 mut/Mb (2.00–6.00 mut/Mb). TMB-H was more common in patients with ILC than in those with IDC (18.2% vs. 10.1%, P < 0.001), particularly in the ER+ /HER2− subtype. Multivariate analysis revealed that the pathological diagnosis of ILC ( P = 0.006), tissue samples collected from metastatic sites ( P < 0.001), and older age (50 years, P < 0.001) were independent factors for TMB-H.
Conclusions
Patients with ILC were more likely to have TMB-H than those with IDC. The findings of this study would be invaluable in selecting treatment strategies for patients with ILC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, 65 Tsurumai-Cho, Showa-Ku, Nagoya, Aichi, 466-8550, Japan. takano.yuko.h3@f.mail.nagoya-u.ac.jp.
- Department of Breast and Endocrine Surgery, Nagoya University Hospital, 65 Tsurumai-Cho, Showa-Ku, Nagoya, Aichi, 466-8550, Japan. takano.yuko.h3@f.mail.nagoya-u.ac.jp.
- Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, 65 Tsurumai-Cho, Showa-Ku, Nagoya, Aichi, 466-8550, Japan.
- Department of Breast and Endocrine Surgery, Nagoya University Hospital, 65 Tsurumai-Cho, Showa-Ku, Nagoya, Aichi, 466-8550, Japan.
Förderung
- Nagoya University
Zitieren
APA
Takano, Y., Mizuno, K., Iwase, M., Morita, S., Torii, N., Kikumori, T., & Ando, Y. (2025). Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breast. Breast Cancer. https://doi.org/10.1007/s12282-025-01706-6
Vancouver
Takano Y, Mizuno K, Iwase M, Morita S, Torii N, Kikumori T, et al. Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breast. Breast Cancer. 2025. doi:10.1007/s12282-025-01706-6
BibTeX
@article{Takano2025,
author = {Takano, Yuko and Mizuno, Kazuyuki and Iwase, Madoka and Morita, Sachi and Torii, Nao and Kikumori, Toyone and Ando, Yuichi},
title = {Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breast},
journal = {Breast Cancer},
year = {2025},
doi = {10.1007/s12282-025-01706-6}
}
EUVIMED